Immunovant (IMVT) Cash from Financing Activities (2019 - 2026)

Immunovant's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 99.19% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $595.8 million (up 31.08% YoY) and the FY2026 annual result came in at $595.8 million, up 31.08% from the prior year.
• Cash from Financing Activities was $3.6 million for Q1 2026 at Immunovant, down from $564.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $564.6 million in Q4 2025 and bottomed at $21000.0 in Q2 2022.
• A 5-year average of $106.2 million and a median of $2.5 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 99.48% — and 2025, when it soared 29065.83%.
• Immunovant's Cash from Financing Activities stood at $70.6 million in 2022, then soared by 565.21% to $469.8 million in 2023, then plunged by 99.48% to $2.5 million in 2024, then soared by 22814.08% to $564.6 million in 2025, then slumped by 99.36% to $3.6 million in 2026.
• Business Quant data shows IMVT's Cash from Financing Activities at $3.6 million in Q1 2026, $564.6 million in Q4 2025, and $24.6 million in Q3 2025.